Liothyronine
As of the edition of 20 October 2026, Liothyronine is a small molecule: marketed, first approved in 1973 (CH); acts on THRA and THRB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- Brand name
- Cytomel
- First approved
- 1 June 1973 (CH)
- Approvals on record
- 8 in 4 regions
- Holder of the most recent approval
- Merck KGaA; 5 holders in all
- Registered trials
- 38, 6 stopped early
- Disease areas
- Hormones; Cancer; Mental health; Heart and blood vessels; Inherited and neonatal; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Liothyronine.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 6 | 2 | 2 |
| Phase 1 | 8 | 6 | 0 | 2 |
| Phase 2 | 10 | 6 | 3 | 1 |
| Phase 3 | 6 | 5 | 1 | 0 |
| Phase 4 | 4 | 3 | 0 | 1 |
| All trials | 38 |